Prognostic Evaluation Based on Dual-Time ¹⁸F-FDG PET/CT Radiomics Features in Patients with Locally Advanced Pancreatic Cancer Treated by Stereotactic Body Radiation Therapy

Table 3

Univariate and multivariate regression analysis for the Rad-score, clinical risk factors, and conventional PET features in the 70 LAPC patients.

Parameters	Univariate analysis		Multivariate analysis
	HR (95% CI)	value	HR (95% CI)	value
Age	1 (1–1)	0.084
Sex	0.99 (0.6–1.7)	0.98
ECOG	0.89 (0.63–1.3)	0.5
Tumor diameter	1.3 (1.1–1.5)	0.012	1.1 (0.86–1.4)	0.414
Location	1.1 (0.64–2)	0.68
T stage	1.8 (1.3–2.4)	<0.01	0.99 (0.63–1.6)	0.97
N stage	1.7 (1.1–2.9)	0.031	1.2 (0.66–2.1)	0.61
CA19-9	1 (1–1)	0.063
Chemotherapy	0.39 (0.22–0.69)	0.001	0.55 (0.26–1.2)	0.11
Dose	0.9 (0.85–0.95)	<0.01	0.47 (0.21–1)	0.056
SUVmax (early)	2.6 (0.88–7.5)	0.083
SUVmean (early)	2.5 (0.85–7.1)	0.097
MTV (early)	2.5 (0.65–9.3)	0.19
TLG (early)	3.6 (1.1–1.2)	0.037	0.77 (0.095–6.3)	0.806
SUVmax (delay)	5.1 (1.6–17)	0.007	2.1 (0.1–43)	0.632
SUVmean(delay)	3.2 (1–9.9)	0.048	4 (0.075–210)	0.494
MTV (delay)	8.9 (2.1–3.7)	0.003	-	0.537
TLG (delay)	9.8 (2.5–38)	0.001	-	0.717
Rad_score (dual)	3.2 (2.1–5)	<0.001	4.1 (2.1–8.1)	<0.001

ECOG, eastern cooperative oncology group; CA19-9, carbohydrate antigen 19–9; dose, radiotherapy dose (Gy); MTV, metabolic tumor volume; TLG, total lesion glycolysis.